These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23419371)

  • 1. Multiple sclerosis: preventing progression and disability in MS-when to treat?
    Pugliatti M
    Nat Rev Neurol; 2013 Mar; 9(3):129-30. PubMed ID: 23419371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients.
    Rzepiński Ł; Zawadka-Kunikowska M; Maciejek Z; Newton JL; Zalewski P
    Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159275
    [No Abstract]   [Full Text] [Related]  

  • 4. Onset of secondary progressive phase and long-term evolution of multiple sclerosis.
    Scalfari A; Neuhaus A; Daumer M; Muraro PA; Ebers GC
    J Neurol Neurosurg Psychiatry; 2014 Jan; 85(1):67-75. PubMed ID: 23486991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M
    Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis.
    Paling D; Solanky BS; Riemer F; Tozer DJ; Wheeler-Kingshott CA; Kapoor R; Golay X; Miller DH
    Brain; 2013 Jul; 136(Pt 7):2305-17. PubMed ID: 23801742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The natural history of multiple sclerosis: update 1998.
    Weinshenker BG
    Semin Neurol; 1998; 18(3):301-7. PubMed ID: 9817534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapses add to permanent disability in relapsing multiple sclerosis patients.
    Koch-Henriksen N; Sørensen PS; Magyari M
    Mult Scler Relat Disord; 2021 Aug; 53():103029. PubMed ID: 34116481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spinal cord atrophy in multiple sclerosis and relationship with disability across clinical phenotypes.
    Bernitsas E; Bao F; Seraji-Bozorgzad N; Chorostecki J; Santiago C; Tselis A; Caon C; Zak I; Millis S; Khan O
    Mult Scler Relat Disord; 2015 Jan; 4(1):47-51. PubMed ID: 25787052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current management of multiple sclerosis].
    Maarouf A; Audoin B; Pelletier J
    Rev Prat; 2022 Apr; 72(4):399-404. PubMed ID: 35638983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between relapsing-remitting and chronic progressive multiple sclerosis as determined with quantitative MR imaging.
    Miki Y; Grossman RI; Udupa JK; van Buchem MA; Wei L; Phillips MD; Patel U; McGowan JC; Kolson DL
    Radiology; 1999 Mar; 210(3):769-74. PubMed ID: 10207480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis.
    Carotenuto A; Signoriello E; Lanzillo R; Vaia Y; Moccia M; Bonavita S; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Aug; 43():102211. PubMed ID: 32474285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis.
    Lizak N; Malpas CB; Sharmin S; Havrdova EK; Horakova D; Izquierdo G; Eichau S; Lugaresi A; Duquette P; Girard M; Prat A; Larochelle C; Trojano M; Grand'Maison F; Grammond P; Sola P; Ferraro D; Hupperts R; Bergamaschi R; Boz C; Van Pesch V; Spitaleri D; Terzi M; Kalincik T;
    JAMA Neurol; 2020 Nov; 77(11):1398-1407. PubMed ID: 32716480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of long-term disability in Chinese patients with multiple sclerosis: A prospective cohort study.
    Zhang Y; Xu Y; Xu T; Yin H; Zhu Y; Peng B; Cui L
    Mult Scler Relat Disord; 2020 Nov; 46():102461. PubMed ID: 32862039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and disability progression in multiple sclerosis in Tunisia: do we really have a more aggressive disease course?
    Sidhom Y; Damak M; Riahi A; Hizem Y; Mrissa R; Mhiri C; Gouider R
    J Neurol Sci; 2014 Aug; 343(1-2):110-4. PubMed ID: 24980939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disability as an outcome in MS clinical trials.
    Ebers GC; Heigenhauser L; Daumer M; Lederer C; Noseworthy JH
    Neurology; 2008 Aug; 71(9):624-31. PubMed ID: 18480462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive symptoms and correlates of physical disability in individuals with multiple sclerosis.
    Fraser C; Stark S
    J Neurosci Nurs; 2003 Dec; 35(6):314-20. PubMed ID: 14713097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.